inflammatory diseases articles & resources on Made-in-China.com

Can-Fite Submits Phase III Protocol Design And Registration Plan To EMA For CF101 To Treat Rheumatoid Arthritis

Mar 21, 2016

Can-Fite BioPharma has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company's lead compound CF101 in the treatment of rheumatoid arthritis following a ...

Tags: Phase III trail, CF101, Can-Fite

XOMA Received Orphan Drug Designation for Its IL-1 Beta Modulating Antibody 'Gevokizumab'

Feb 27, 2014

US-based XOMA Corporation (XOMA) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its IL-1 beta modulating antibody 'gevokizumab' for the treatment of pyoderma gangrenosum (PG). Gevokizumab is a ...

Tags: Orphan Drug, Medicine

Soligenix Announced Significant Steps Forward in The Development of ThermoVax

Jan 17, 2014

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, ...

Tags: Soligenix, NIAID, ThermoVax, Drs.John Carpenter

"Microparticle" Therapy Might Significantly Reduce The Damage Caused by a Heart Attack

Jan 16, 2014

Quick treatment with a new "microparticle" therapy might significantly reduce the damage caused by a heart attack, according to a new study conducted in mice. After a heart attack, much of the damage to the heart muscle is caused by ...

Tags: microparticle therapy, heart attack, reduce damage

E. Coli Has Earned Its Reputation as a Deadly Pathogen Lurking in Contaminated Foods

Jan 6, 2014

E. coli has earned its reputation as a deadly pathogen lurking in contaminated foods, but a multi-year study may give it some positive press as a source of medical knowledge and potential therapeutics. Researchers at Kansas State ...

Tags: Agriculture, Food

Covagen Announced It Has Secured CHF42m in a Tranched Series B Financing

Dec 11, 2013

Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...

Tags: Covagen, Medicine

Multiplexed Single Molecule Immunoassay Was Launched by Quanterix

Sep 18, 2013

US-based Quanterix has launched multiplexed single molecule immunoassay technology for improving diagnosis and potential treatment of complex diseases. The multiplexed single molecule immunoassays study, which was partly funded by the ...

Tags: Health, Medicine

Can-Fite BioPharma Received a Patent Entitled From The European Patent Office

Sep 6, 2013

Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...

Tags: Can-Fite BioPharma

Momenta Has Announced The Issuance of Sialylation Technology

Jun 27, 2013

Biotechnology company Momenta Pharmaceuticals has announced the issuance of a patent from the US Patent and Trademark Office to The Rockefeller University for sialylation technology. The patent expires in 2028 and covers methods of ...

Tags: Momenta, US Patent, Sialylation Technology

Trino Therapeutics Received More Than $12m Funding to Advance Ulcerative Colitis Drug

May 29, 2013

Drug discovery and early drug development company Trino Therapeutics has received more than €9m ($12m) funding from investors, including Fountain Healthcare Partners and founding investor, the Wellcome Trust, to advance the development ...

Tags: Trino, Colitis Drug

US FDA Has Approved Novartis' Ilaris for Treatment of Active Systemic Juvenile Arthritis

May 14, 2013

The USFDA has approved Novartis' Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients with two years age and more. The first interleukin-1 beta inhibitor is the only treatment approved ...

Tags: FDA, Medicine

Dr. Michael A. Eldon Will Present a Webinar Focuses on Pk/Pd Modeling and Simulation

May 13, 2013

San Carlos, California, United States of America (Free-Press-Release.com) May 7, 2013 -- Rosa & Co. LLC today announced that Dr. Michael A. Eldon, Principal Scientific Fellow, VP, Clinical Pharmacology, Nektar Therapeutics, will present a ...

Tags: Health, Medicine

Rosa & Co. LLC Announced Physiomap and Physiopd Collaboration Results

May 13, 2013

FOR IMMEDIATE RELEASE San Carlos, California, United States of America (Free-Press-Release.com) May 9, 2013 -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that ...

Tags: Construction, Decoration

Theradiag's Anti-CCP in Vitro Diagnostic Kit is ratified by CE Mark

Apr 24, 2013

Theradiag has received a CE mark approval for its anti cyclic citrullinated peptide (anti-CCP) in vitro diagnostic (IVD) kit in rheumatoid arthritis. The test further expands the Fidis portfolio of diagnostic tests for auto-immunes ...

Tags: Theradiag, CE Mark, Anti-CCP

Astellas Pharma and UCB Have Introduced Cimzia Rheumatoid Arthritis Therapy in Japan

Mar 12, 2013

Astellas Pharma and UCB have introduced Cimzia (certolizumab pegol) rheumatoid arthritis therapy in Japan. The PEGylated Fc-free anti-TNF medication is indicated for adult rheumatoid arthritis patients who showed poor response to ...

Tags: Astellas Pharma, Astellas, rheumatoid arthritis therapy

inflammatory diseases

Related Products